Statements (113)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:associated_with |
gptkb:healthcare_organization
gptkb:triple-negative_breast_cancer gptkb:vaccine ovarian cancer clinical trials targeted therapies increased mortality risk tumor characteristics reproductive health issues uterine cancer family planning decisions radiation sensitivity PARP inhibitors fallopian tube cancer male breast cancer psychosocial impact chemotherapy response reduced survival rates risk-reducing strategies |
| gptkbp:availability |
genetic testing
|
| gptkbp:clinical_trial |
gptkb:hereditary_breast_and_ovarian_cancer_syndrome
|
| gptkbp:code |
BRC A1 protein
|
| gptkbp:counseling_services |
high risk individuals
|
| gptkbp:discovered_by |
gptkb:healthcare_organization
gptkb:Mary-Claire_King breast cancer research patient management strategies linkage analysis awareness of hereditary cancer syndromes genetic testing guidelines |
| gptkbp:field_of_study |
gptkb:physicist
|
| gptkbp:function |
DNA repair
|
| gptkbp:genetic_diversity |
increased cancer risk
frameshift mutation missense mutation germline mutation nonsense mutation familial breast cancer |
| gptkbp:has_role |
repairing double-strand breaks
|
| https://www.w3.org/2000/01/rdf-schema#label |
BRCA1 gene
|
| gptkbp:interacts_with |
BRC A2 protein
|
| gptkbp:is_a_route_for |
homologous recombination
|
| gptkbp:is_aimed_at |
PARP inhibitors
|
| gptkbp:is_associated_with |
gptkb:healthcare_organization
gptkb:hereditary_breast_and_ovarian_cancer_syndrome gptkb:cervical_cancer neuroendocrine tumors male breast cancer |
| gptkbp:is_essential_for |
genomic stability
|
| gptkbp:is_involved_in |
DNA damage response
apoptosis cellular homeostasis cellular metabolism chromatin remodeling immune response homologous recombination cellular proliferation cellular response to stress cellular senescence chromosomal stability cellular differentiation DNA double-strand break repair cellular signaling cellular repair mechanisms telomere maintenance m RNA splicing |
| gptkbp:is_linked_to |
gptkb:healthcare_organization
increased cancer risk endometrial cancer esophageal cancer bladder cancer gastrointestinal cancer fallopian tube cancer |
| gptkbp:is_part_of |
tumor suppressor genes
DNA damage checkpoint DNA repair pathways BRC A1-associated protein complex BRC A1/ BRC A2 repair complex DNA repair complex |
| gptkbp:is_recognized_by |
gptkb:Ashkenazi_Jewish_population
gptkb:1990 familial breast cancer cases |
| gptkbp:is_represented_in |
brain tissue
breast tissue embryonic stem cells lung tissue ovarian tissue placental tissue testicular tissue |
| gptkbp:is_studied_in |
gptkb:physicist
clinical trials population genetics cancer genetics cancer prevention strategies genetic counseling. |
| gptkbp:located_in |
17q21.31
chromosome 17 human chromosome 17 |
| gptkbp:nutritional_value |
BRC A1 protein
|
| gptkbp:part_of |
BRC A1/ BRC A2 pathway
|
| gptkbp:promoter |
BRC A1
|
| gptkbp:regulates |
cell cycle
estrogen |
| gptkbp:related_to |
BRC A2 gene
|
| gptkbp:research_focus |
cancer genetics
|
| gptkbp:risk_factor |
family history
|
| gptkbp:screenings |
MRI screening
mammography screening |
| gptkbp:seed_dispersal |
tumor suppressor gene
|
| gptkbp:treatment |
preventive mastectomy
preventive oophorectomy |
| gptkbp:year_created |
gptkb:1990
|